Actively Recruiting
Registry of Cell Therapy in Non-Ischemic Dilated Cardiomyopathy
Led by University Medical Centre Ljubljana · Updated on 2024-07-03
250
Participants Needed
1
Research Sites
1165 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Although several studies have demonstrated beneficial effects of stem cell therapy in patients with non-ischemic dilated cardiomyopathy, the long term benefits and predictors of response to therapy remain undefined. The aim of this registry is to pool long-term clinical data in patients with non-ischemic dilated cardiomyopathy undergoing autologous cell therapy in an attempt to better define predictors of response to such treatment.
CONDITIONS
Official Title
Registry of Cell Therapy in Non-Ischemic Dilated Cardiomyopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 65 years old
- Diagnosis of dilated cardiomyopathy according to the European Society of Cardiology
- Optimal medical management for at least 6 months
- Left ventricular ejection fraction less than 40%
- New York Heart Association functional Class III on stable medical therapy for at least 3 months before referral
You will not qualify if you...
- Acute multi-organ failure
- History of hematologic neoplasms
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UMC Ljubljana
Ljubljana, Slovenia, 1000
Actively Recruiting
Research Team
B
Bojan Vrtovec, MD, PhD
CONTACT
G
Gregor Poglajen, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here